04/21/21 1:00 AMNYSE : QGEN partnershipQIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early diagnosis of Lyme Borreliosis QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the launch of the LIAISON ® LymeDetect ® Assay for markets accepting the CE Mark, as an aid to detect early Lyme Borreliosis infection (Lyme) on LIAISON ® analyzer systems.Lyme is a tick-borneRHEA-AIneutral
04/20/21 4:05 PMNYSE : QGEN QIAGEN Launches artus Prep&Amp as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing CapacityQIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the artus ® SARS-CoV-2 Prep&Amp UM Kit which uses a liquid based sample preparation technology to simplify and increase COVID-19 testing throughput. The artus ® SARS-CoV-2 Prep&Amp UM Kit has been CE-IVD registered forRHEA-AIneutral
04/20/21 5:55 AMNYSE : QGEN conferencesQIAGEN N.V. to Report First Quarter 2021 ResultsQIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the first quarter 2021 on Monday, May 3, at approximately 22:05 Central European Time (CET) / 16:05 Eastern Daylight Time (EDT).A conference call is planned for Tuesday, MayRHEA-AIneutral
04/06/21 4:05 PMNYSE : QGEN covid-19QIAGEN Adds to COVID-19 Portfolio With New Ultra-Fast Sequencing Solution for High-Throughput Genomic SurveillanceQIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced the launch of QIAseq DIRECT SARS-CoV-2 Kit, a viral genome enrichment and library preparation solution that significantly reduces library turnaround times and plastics use compared with ARTIC project protocols (primer-basedRHEA-AIneutral
03/29/21 2:00 AMNYSE : QGEN covid-19QIAGEN Receives FDA Emergency Use Authorization for NeuMoDx Multiplex Test Expanding COVID-19 PortfolioQIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the Emergency Use Authorization by the U.S. FDA for the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Assay that will help healthcare professionals quickly identify and differentiate individuals suspected by a healthcare provider ofRHEA-AIneutral
03/05/21 6:05 AMNYSE : QGEN QIAGEN Announces 20-F Annual Report Filing for 2020 ResultsQIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2020, with the U.S. Securities and Exchange Commission. The document can be accessed onRHEA-AIneutral
03/03/21 4:10 PMNYSE : QGEN, QIA QIAGEN Launches QIAsphere Cloud-Based Connectivity Solution to Enhance QIAstat-Dx Capabilities in Digital DiagnosticsQIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched its QIAsphere cloud-based platform that will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week.QIAsphere sets new standards for syndromic testing digital health, providingRHEA-AIneutral
03/02/21 4:11 PMNYSE : QGEN, QIA QIAGEN Launches QIAcube Connect MDx Platform for Automated Sample Processing in Diagnostic LabsQIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of the QIAcube Connect MDx, a flexible platform for automated sample processing that will now be available to molecular diagnostic laboratories in the U.S. and Canada, the European Union and other marketsRHEA-AIneutral
02/24/21 1:45 AMNYSE, Nasdaq : QGEN, QIA, INO QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO’s VGX-3100 for Advanced Cervical Dysplasia QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technologyRHEA-AIvery positive
02/24/21 1:45 AMNasdaq, NYSE : INO, QGEN high shortINOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasiaQIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquidRHEA-AIvery positive